Mesoblast Appoints Dr. Teresa Montagut to Lead Clinical Development and Medical Affairs for Cell Therapy Expansion
核心洞察
Mesoblast Limited (搜索) has appointed Dr. Teresa Montagut (搜索) as Head of Clinical Development and Medical Affairs to lead the company's medical affairs organization and foster clinical collaborations for expanding cell therapy programs.
Dr. Montagut brings extensive pharmaceutical development experience from Regeneron, Novartis, Genentech, and Atara Biotherapeutics, with expertise in cancer immunotherapy and investigator-initiated trials.
The appointment aims to unlock value in Mesoblast's cell therapy programs for new pediatric and adult inflammatory conditions, building on the success of FDA-approved Ryoncil (搜索) for steroid-refractory acute graft versus host disease (搜索).
Mesoblast Limited (搜索), a global leader in allogeneic cellular medicines for inflammatory diseases (搜索), has appointed Dr. Teresa Montagut (搜索) as Head of Clinical Development and Medical Affairs in a newly established senior position. The appointment strengthens the company's leadership team as it works to expand the therapeutic applications of its cell therapy portfolio across pediatric and adult inflammatory conditions.
Strategic Leadership Role
Dr. Montagut will report to Chief Medical Officer Dr. Eric Rose and lead Mesoblast's medical affairs organization globally. Her responsibilities encompass fostering clinical collaborations, spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals worldwide. The role is specifically designed to unlock the value of Mesoblast's cell therapy programs in new indications through partnerships with investigators and key opinion leaders.
"Teri's commitment to scientific excellence and her expertise in investigator-initiated clinical trial execution is central to successful implementation of our strategy to expand the range of indications of our FDA approved product Ryoncil (搜索)® in pediatric and adult inflammatory conditions, as well as advancing our pipeline of transformative cellular therapies," said Dr. Silviu Itescu, Chief Executive Officer of Mesoblast.
Extensive Industry Experience
Dr. Montagut joins Mesoblast from Regeneron, where she served as Global Head of Early Pipeline Studies in Oncology and Head of Medical Affairs for Investigator Sponsored Studies in gastrointestinal and genitourinary areas. Her career spans leadership roles across multiple major pharmaceutical companies, including directing cancer immunotherapy programs at Novartis, Genentech, and Atara Biotherapeutics.
Her academic credentials reflect a strong foundation in translational medicine. Dr. Montagut earned her MD from Universidad Nacional Autónoma de México and completed a PhD in Tumor Immunology from Memorial Sloan Kettering Cancer Center/Cornell University. She further developed her expertise through fellowships at Massachusetts General Hospital, Howard Hughes Medical Institute, and Rockefeller University.
Expanding Therapeutic Applications
The appointment comes as Mesoblast works to broaden the clinical applications of its cellular medicine platform. The company's Ryoncil (搜索)® (remestemcel-L-rknd (搜索)) represents the first FDA-approved mesenchymal stromal cell (搜索) therapy, currently indicated for treating steroid-refractory acute graft versus host disease (搜索) in pediatric patients 2 months and older.
Mesoblast is developing Ryoncil (搜索) for additional inflammatory diseases (搜索) including steroid-refractory acute graft versus host disease (搜索) in adults and biologic-resistant inflammatory bowel disease (搜索). The company's pipeline also includes rexlemestrocel-L, which is being developed for heart failure (搜索) and chronic low back pain (搜索).
Global Health Commitment
Beyond her industry roles, Dr. Montagut demonstrates commitment to global health initiatives through her service on the Board of Directors of the Global Pediatric Alliance. This organization focuses on supporting maternal and pediatric healthcare in under-served indigenous communities in Latin America, particularly Mexico.
Technology Platform and Manufacturing
Mesoblast's proprietary mesenchymal lineage cell therapy technology platform addresses severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system. The company's manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf cellular medicines with defined pharmaceutical release criteria, designed to be readily available to patients worldwide.
The company maintains a robust intellectual property portfolio with over 1,000 granted patents or patent applications covering mesenchymal stromal cell (搜索) compositions, manufacturing methods, and indications. These patents provide commercial protection extending through at least 2044 in major markets. Mesoblast has established commercial partnerships in Japan, Europe, and China, with operations in Australia, the United States, and Singapore.